levopidon 45 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 45 mg
levopidon 50 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 50 mg
levopidon 55 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 55 mg
levopidon 60 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 60 mg
levopidon 65 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 65 mg
levopidon 70 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 70 mg
levopidon 75 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 75 mg
morfin "eql pharma" 10 mg tabletter
eql pharma ab - morphinhydrochloridtrihydrat - tabletter - 10 mg
morfin "eql pharma" 30 mg tabletter
eql pharma ab - morphinhydrochloridtrihydrat - tabletter - 30 mg
pioglitazone teva pharma
teva pharma b.v. - pioglitazonhydrochlorid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. efter initiering af behandling med pioglitazon, patienter bør revurderes efter 3 til 6 måneder for at vurdere tilstrækkeligheden af respons på behandlingen (e. reduktion i hba1c). hos patienter, der undlader at vise et passende svar, pioglitazon bør seponeres. i lyset af potentielle risici med langvarig terapi, ordinerende læger bør bekræftes ved en efterfølgende rutinemæssige vurderinger, der har gavn af pioglitazon er fastholdt.